GSK meanwhile has previously suggest that the HBV therapy could collectively achieve sales of more than £2 billion ($2.45 billion) at peak, part of a new wave of therapies that it reckons could ...
GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback